The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.